OCTREOTIDE ACETATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for OCTREOTIDE ACETATE (OCTREOTIDE ACETATE).

How it works

Synthetic octapeptide analog of somatostatin with greater potency. Binds to somatostatin receptors (SSTR2 and SSTR5), inhibiting growth hormone, glucagon, insulin, and gastrointestinal peptide secretion. Also reduces splanchnic blood flow and suppresses tumor growth in neuroendocrine tumors.

What the body does with it

Metabolism	Primarily hepatic metabolism by CYP3A4; also metabolized by peptidases. Approximately 32% excreted unchanged in urine.
Excretion	Approximately 32% excreted unchanged in urine; the remainder is cleared via biliary/fecal elimination.
Half-life	Terminal elimination half-life is 1.7–1.9 hours (subcutaneous) and 1.5–2.0 hours (intravenous). For long-acting release (LAR) formulation, apparent half-life is longer due to slow release.
Protein binding	65% bound to plasma proteins, primarily to alpha-1-acid glycoprotein and albumin.
Volume of Distribution	0.2–0.4 L/kg, indicating distribution primarily into extracellular fluid.
Bioavailability	Subcutaneous: 100% (absolute); Intramuscular LAR: 25–30% (relative to subcutaneous due to slow release).
Onset of Action	Subcutaneous: 30 minutes; Intravenous: immediate; Intramuscular (LAR): 2 weeks for therapeutic effect.
Duration of Action	Subcutaneous: 8–12 hours; Intravenous: 8–12 hours; Intramuscular (LAR): 28 days.

Classification & Brands

Dosing & administration

Initial: 50 mcg subcutaneously 2-3 times daily; titrate to 100-200 mcg 2-3 times daily. For acromegaly: 50 mcg subcutaneously 3 times daily, increase to 100-500 mcg 3 times daily. For carcinoid tumors: 100-600 mcg subcutaneously 2-4 times daily. Intravenous infusion: 25-50 mcg/hr continuous IV.

Dosage form	INJECTABLE
Renal impairment	CrCl <30 mL/min: No dose adjustment recommended in labeling; however, monitor closely due to potential accumulation. No specific guidelines for CrCl 30-50 mL/min.
Liver impairment	Child-Pugh A or B: No specific adjustment; Child-Pugh C: Use with caution, reduce initial dose and titrate slowly based on response and tolerability.
Pediatric use	Not FDA-approved for pediatric use. Limited data: Octreotide for secretory diarrhea: 1-2 mcg/kg subcutaneously initially, then titrate to 5-10 mcg/kg daily in divided doses. For variceal bleeding: 25-50 mcg/m2/hour continuous IV; maximum 75 mcg/m2/hour.
Geriatric use	No specific dose adjustment recommended; consider increased sensitivity to adverse effects (bradycardia, electrolyte disturbances). Start at low end of dosing range and titrate cautiously. Renal function may be reduced, monitor closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for OCTREOTIDE ACETATE (OCTREOTIDE ACETATE).

Breastfeeding	It is unknown if octreotide is excreted in human breast milk. M/P ratio not available. Caution is advised; consider discontinuing breastfeeding or the drug based on importance to mother.
Teratogenic Risk	Octreotide acetate is not recommended during pregnancy, especially in the first trimester, due to limited human data. Animal studies have shown no evidence of teratogenicity at clinically relevant doses. Use only if clearly needed.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to octreotide or any component","Contraindicated in patients with sulfonamide allergy (for specific formulations containing sulfites)"]

Clinical Precautions

Precautions

["Cholelithiasis: increased risk due to inhibition of gallbladder motility and bile secretion","Glucose metabolism disturbances: hyper- or hypoglycemia","Cardiovascular effects: bradycardia, conduction abnormalities","Hypothyroidism: may suppress TSH secretion","Gallbladder sludge or stones","Vitamin B12 deficiency with long-term use"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

OCTREOTIDE ACETATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for OCTREOTIDE ACETATE (OCTREOTIDE ACETATE).

How it works

What the body does with it

Metabolism	Primarily hepatic metabolism by CYP3A4; also metabolized by peptidases. Approximately 32% excreted unchanged in urine.
Excretion	Approximately 32% excreted unchanged in urine; the remainder is cleared via biliary/fecal elimination.
Half-life	Terminal elimination half-life is 1.7–1.9 hours (subcutaneous) and 1.5–2.0 hours (intravenous). For long-acting release (LAR) formulation, apparent half-life is longer due to slow release.
Protein binding	65% bound to plasma proteins, primarily to alpha-1-acid glycoprotein and albumin.
Volume of Distribution	0.2–0.4 L/kg, indicating distribution primarily into extracellular fluid.
Bioavailability	Subcutaneous: 100% (absolute); Intramuscular LAR: 25–30% (relative to subcutaneous due to slow release).
Onset of Action	Subcutaneous: 30 minutes; Intravenous: immediate; Intramuscular (LAR): 2 weeks for therapeutic effect.
Duration of Action	Subcutaneous: 8–12 hours; Intravenous: 8–12 hours; Intramuscular (LAR): 28 days.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	CrCl <30 mL/min: No dose adjustment recommended in labeling; however, monitor closely due to potential accumulation. No specific guidelines for CrCl 30-50 mL/min.
Liver impairment	Child-Pugh A or B: No specific adjustment; Child-Pugh C: Use with caution, reduce initial dose and titrate slowly based on response and tolerability.
Pediatric use	Not FDA-approved for pediatric use. Limited data: Octreotide for secretory diarrhea: 1-2 mcg/kg subcutaneously initially, then titrate to 5-10 mcg/kg daily in divided doses. For variceal bleeding: 25-50 mcg/m2/hour continuous IV; maximum 75 mcg/m2/hour.
Geriatric use	No specific dose adjustment recommended; consider increased sensitivity to adverse effects (bradycardia, electrolyte disturbances). Start at low end of dosing range and titrate cautiously. Renal function may be reduced, monitor closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for OCTREOTIDE ACETATE (OCTREOTIDE ACETATE).

Breastfeeding	It is unknown if octreotide is excreted in human breast milk. M/P ratio not available. Caution is advised; consider discontinuing breastfeeding or the drug based on importance to mother.
Teratogenic Risk	Octreotide acetate is not recommended during pregnancy, especially in the first trimester, due to limited human data. Animal studies have shown no evidence of teratogenicity at clinically relevant doses. Use only if clearly needed.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to octreotide or any component","Contraindicated in patients with sulfonamide allergy (for specific formulations containing sulfites)"]